Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for HeartSciences (HSCS) over the last 4 years, with Q4 2025 value amounting to $1.5 million.

  • HeartSciences' Cash from Financing Activities fell 2065.62% to $1.5 million in Q4 2025 from the same period last year, while for Oct 2025 it was $5.4 million, marking a year-over-year decrease of 5452.53%. This contributed to the annual value of $2.7 million for FY2025, which is 7356.93% down from last year.
  • Latest data reveals that HeartSciences reported Cash from Financing Activities of $1.5 million as of Q4 2025, which was down 2065.62% from $3.6 million recorded in Q3 2025.
  • In the past 5 years, HeartSciences' Cash from Financing Activities ranged from a high of $9.1 million in Q1 2024 and a low of -$121522.0 during Q1 2023
  • Moreover, its 4-year median value for Cash from Financing Activities was $667028.5 (2022), whereas its average is $1.7 million.
  • As far as peak fluctuations go, HeartSciences' Cash from Financing Activities tumbled by 10631.58% in 2023, and later soared by 761016.61% in 2024.
  • HeartSciences' Cash from Financing Activities (Quarter) stood at -$116392.0 in 2022, then skyrocketed by 542.15% to $514629.0 in 2023, then soared by 269.53% to $1.9 million in 2024, then fell by 20.66% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q4 2025, $3.6 million for Q3 2025, and $100028.0 during Q2 2025.